JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 100 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $592,000 | +18.2% | 72,607 | 0.0% | 0.08% | +3.7% |
Q2 2020 | $501,000 | -2.5% | 72,607 | -32.9% | 0.08% | -21.2% |
Q1 2020 | $514,000 | -45.6% | 108,204 | 0.0% | 0.10% | -10.3% |
Q4 2019 | $945,000 | +162.5% | 108,204 | 0.0% | 0.12% | +123.1% |
Q3 2019 | $360,000 | – | 108,204 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |